The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons
European Journal of Pain2014Vol. 19(1), pp. 132–142
Citations Over TimeTop 21% of 2014 papers
Abstract
The selective bradykinin B1 receptor antagonist BI113823 reduces CFA-induced mechanical hyperalgesia which is mediated via antagonism of peripheral as well as spinal bradykinin B1 receptors. The selective modulation of CFA-sensitized spinal NS neurons by BI113823 could be a promising property for the treatment of inflammatory pain.
Related Papers
- → A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia(1988)5,134 cited
- → Neural Mechanisms of Cutaneous Nociceptive Pain(2000)81 cited
- → The dose‐related effects of paracetamol on hyperalgesia and nociception in the rat(1996)41 cited
- → Inflammation modulates the contribution of receptor-subtypes to bradykinin-induced hyperalgesia in the rat(1995)55 cited
- → Environmentally induced antinociception and hyperalgesia in rats and mice(2011)15 cited